Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 86 articles: HTML format Text format

Single Articles

March 2019
1. BIRGE RB, Kasikara C, Davra V, Calianese D, et al
   Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer.
   Cancer Res. 2019 Mar 15. pii: 0008-5472.CAN-18-2614.
   PubMed     Text format     Abstract available
   
   
   
2. MADAK-ERDOGAN Z, Band S, Zhao YC, Smith BP, et al
   Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling.
   Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2849.
   PubMed     Text format     Abstract available
   
   
   
3. YAMAMOTO M, Jin C, Hata T, Yasumizu Y, et al
   MUC1-C INTEGRATES CHROMATIN REMODELING AND PARP1 ACTIVITY IN THE DNA DAMAGE RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS.
   Cancer Res. 2019 Mar 1. pii: 0008-5472.CAN-18-3259.
   PubMed     Text format     Abstract available
   
   
   February 2019
4. BHOLA NE, Jansen VM, Bafna S, Giltnane JM, et al
   Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.
   Cancer Res. 2019;79:876.
   PubMed     Text format    
   
   
   
5. BHOLA NE, Jansen VM, Koch JP, Li H, et al
   Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
   Cancer Res. 2019;79:875.
   PubMed     Text format    
   
   
   
6. JANSEN VM, Bhola NE, Bauer JA, Formisano L, et al
   Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
   Cancer Res. 2019;79:874.
   PubMed     Text format    
   
   
   
7. HANKER AB, Estrada MV, Bianchini G, Moore PD, et al
   Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
   Cancer Res. 2019;79:873.
   PubMed     Text format    
   
   
   
8. HONG BS, Ryu HS, Kim N, Kim J, et al
   Tumor suppressor microRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer.
   Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-0891.
   PubMed     Text format     Abstract available
   
   
   
9. SHINDE A, Hardy SD, Kim D, Akhand SS, et al
   Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer.
   Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2636.
   PubMed     Text format     Abstract available
   
   
   January 2019
10. STEIN RG, Ebert S, Schlahsa L, Scholz CJ, et al
    Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.
    Cancer Res. 2019 Jan 28. pii: 0008-5472.CAN-18-0387.
    PubMed     Text format     Abstract available
    
    
    
11. MAZIVEYI M, Dong S, Baranwal S, Mehrnezhad A, et al
    Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and tumor growth.
    Cancer Res. 2019 Jan 11. pii: 0008-5472.CAN-18-0842.
    PubMed     Text format     Abstract available
    
    
    
12. KHAWALED S, Suh SS, Abdeen SK, Monin J, et al
    WWOX inhibits metastasis of triple-negative breast cancer cells via modulation of microRNAs.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-0614.
    PubMed     Text format     Abstract available
    
    
    December 2018
13. YANG F, Takagaki Y, Yoshitomi Y, Ikeda T, et al
    Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis.
    Cancer Res. 2018 Dec 24. pii: 0008-5472.CAN-18-0620.
    PubMed     Text format     Abstract available
    
    
    
14. EL AYACHI I, Fatima I, Wend P, Alva-Ornelas JA, et al
    The WNT10B network is associated with survival and metastases in chemoresistant triple-negative breast cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-1069.
    PubMed     Text format     Abstract available
    
    
    November 2018
15. NILCHIAN A, Johansson J, Ghalali A, Travica Asanin S, et al
    CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
    Cancer Res. 2018 Nov 1. pii: 0008-5472.CAN-18-1742.
    PubMed     Text format     Abstract available
    
    
    
16. LI J, Ugalde-Morales E, Wen WX, Decker B, et al
    Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.
    Cancer Res. 2018;78:6329-6338.
    PubMed     Text format     Abstract available
    
    
    October 2018
17. 
    Correction: Absence of the Full-Length Breast Cancer-Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members.
    Cancer Res. 2018;78:6025.
    PubMed     Text format    
    
    
    
18. WANG Z, Grosskurth SE, Cheung T, Petteruti P, et al
    Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-1362.
    PubMed     Text format     Abstract available
    
    
    
19. ALI R, Al-Kawaz A, Toss MS, Green AR, et al
    Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0633.
    PubMed     Text format     Abstract available
    
    
    
20. 
    Retraction: Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.
    Cancer Res. 2018;78:5719.
    PubMed     Text format    
    
    
    September 2018
21. ELDER AM, Tamburini BA, Crump LS, Black SA, et al
    Semaphorin 7A promotes macrophage-mediated lymphatic remodeling during postpartum mammary gland involution and in breast cancer.
    Cancer Res. 2018 Sep 25. pii: 0008-5472.CAN-18-1642.
    PubMed     Text format     Abstract available
    
    
    
22. CHEN C, Okita Y, Watanabe Y, Abe F, et al
    Glycoprotein nmb is exposed on the surface of dormant breast cancer cells and induces stem cell-like properties.
    Cancer Res. 2018 Sep 17. pii: 0008-5472.CAN-18-0599.
    PubMed     Text format     Abstract available
    
    
    
23. DINARELLO CA
    An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.
    Cancer Res. 2018;78:5200-5202.
    PubMed     Text format     Abstract available
    
    
    
24. GAUDET MM, Gierach GL, Carter BD, Luo J, et al
    Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-18-0502.
    PubMed     Text format     Abstract available
    
    
    
25. 
    Retraction: Zerumbone Abolishes RANKL-Induced NF-kappaB Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice.
    Cancer Res. 2018;78:5186.
    PubMed     Text format    
    
    
    August 2018
26. HUANG F, Shi Q, Li Y, Xu L, et al
    HER2/EGFR-AKT signaling switches TGF-beta from inhibiting cell proliferation to promoting cell migration in breast cancer.
    Cancer Res. 2018 Aug 31. pii: 0008-5472.CAN-18-0136.
    PubMed     Text format     Abstract available
    
    
    
27. YANOVICH G, Agmon H, Harel M, Sonnenblick A, et al
    Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification.
    Cancer Res. 2018 Aug 28. pii: 0008-5472.CAN-18-1079.
    PubMed     Text format     Abstract available
    
    
    
28. AL ABSI A, Wurzer H, Guerin CL, Hoffmann C, et al
    Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer-mediated cytotoxicity.
    Cancer Res. 2018 Aug 13. pii: 0008-5472.CAN-18-0441.
    PubMed     Text format     Abstract available
    
    
    
29. MURALI B, Ren Q, Luo X, Faget DV, et al
    Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss.
    Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-18-0234.
    PubMed     Text format     Abstract available
    
    
    
30. ZHANG FL, Cao JL, Xie HY, Sun R, et al
    Cancer-associated MORC2 mutant M276I regulates an hnRNPM-mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer.
    Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-17-1394.
    PubMed     Text format     Abstract available
    
    
    
31. ZHOU R, Bagga P, Nath K, Hariharan H, et al
    Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging (GluCEST MRI) detects glutaminase inhibition in a mouse model of triple-negative breast cancer.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3988.
    PubMed     Text format     Abstract available
    
    
    July 2018
32. UBELLACKER JM, Baryawno N, Severe N, DeCristo MJ, et al
    Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer.
    Cancer Res. 2018 Jul 31. pii: 0008-5472.CAN-18-0548.
    PubMed     Text format     Abstract available
    
    
    
33. CROSET M, Pantano F, Kan CWS, Bonnelye E, et al
    MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes.
    Cancer Res. 2018 Jul 24. pii: 0008-5472.CAN-17-3058.
    PubMed     Text format     Abstract available
    
    
    
34. XING F, Liu Y, Wu SY, Wu K, et al
    Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-1102.
    PubMed     Text format     Abstract available
    
    
    
35. WU TC, Xu K, Martinek J, Young RR, et al
    IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer.
    Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-18-0413.
    PubMed     Text format     Abstract available
    
    
    
36. XING Z, Zhang Y, Liang K, Yan L, et al
    Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer.
    Cancer Res. 2018 Jul 2. pii: 0008-5472.CAN-17-0385.
    PubMed     Text format     Abstract available
    
    
    June 2018
37. ZHANG W, Wu M, Chong QY, Zhang M, et al
    Loss of estrogen-regulated MIR135A1 at 3p21.1 promotes tamoxifen resistance in breast cancer.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-18-0069.
    PubMed     Text format     Abstract available
    
    
    
38. SUN R, Xie HY, Qian JX, Huang YN, et al
    FBXO22 possesses both pro-tumorigenic and anti-metastatic roles in breast cancer progression.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3647.
    PubMed     Text format     Abstract available
    
    
    
39. IM YK, Najyb O, Gravel SP, McGuirk S, et al
    Interplay between ShcA signaling and PGC-1alpha triggers targetable metabolic vulnerabilities in breast cancer.
    Cancer Res. 2018 Jun 21. pii: 0008-5472.CAN-17-3696.
    PubMed     Text format     Abstract available
    
    
    
40. 
    Correction: TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Cancer Res. 2018;78:3403.
    PubMed     Text format    
    
    
    
41. HE JP, Hou PP, Chen QT, Wang WJ, et al
    Flightless-I blocks p62-mediated recognition of LC3 to impede selective autophagy and promote breast cancer progression.
    Cancer Res. 2018 Jun 13. pii: 0008-5472.CAN-17-3835.
    PubMed     Text format     Abstract available
    
    
    
42. GOOD CR, Panjarian S, Kelly AD, Madzo J, et al
    TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-2082.
    PubMed     Text format     Abstract available
    
    
    
43. LU H, Tran L, Park Y, Chen I, et al
    Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF-1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
    Cancer Res. 2018 Jun 7. pii: 0008-5472.CAN-18-0270.
    PubMed     Text format     Abstract available
    
    
    May 2018
44. JASTRZEBSKI K, Thijssen B, Kluin RJ, de Lint K, et al
    Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.
    Cancer Res. 2018 May 29. pii: 0008-5472.CAN-17-2698.
    PubMed     Text format     Abstract available
    
    
    
45. MATSUNAGA N, Ogino T, Hara Y, Tanaka T, et al
    Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the anti-tumor effects of aldehyde dehydrogenase.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-17-4034.
    PubMed     Text format     Abstract available
    
    
    April 2018
46. ZHENG YZ, Xue MZ, Shen HJ, Li XG, et al
    PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.
    Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3514.
    PubMed     Text format     Abstract available
    
    
    
47. AVANZATO D, Pupo E, Ducano N, Isella C, et al
    High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis.
    Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3018.
    PubMed     Text format     Abstract available
    
    
    March 2018
48. WANG LH, Tseng CW, Kuo WH, Chan SH, et al
    Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
    Cancer Res. 2018 Mar 29. pii: 0008-5472.CAN-17-2906.
    PubMed     Text format     Abstract available
    
    
    
49. ZHANG B, Chen MY, Sheng YJ, Zhuo XB, et al
    A large-scale, exome-wide association study of Han Chinese women identifies three novel loci predisposing to breast cancer.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-1721.
    PubMed     Text format     Abstract available
    
    
    
50. REN D, Zhu X, Kong R, Zhao Z, et al
    Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
    Cancer Res. 2018 Mar 22. pii: 0008-5472.CAN-17-2994.
    PubMed     Text format     Abstract available
    
    
    
51. HOU J, Williams J, Botvinick E, Potma E, et al
    Visualization of breast cancer metabolism using multimodal non-linear optical microscopy of cellular lipids and redox state.
    Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2618.
    PubMed     Text format     Abstract available
    
    
    
52. LUAN H, Mohapatra B, Bielecki TA, Mushtaq I, et al
    Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-16-2140.
    PubMed     Text format     Abstract available
    
    
    February 2018
53. HORNSVELD M, Smits LM, Meerlo M, van Amersfoort M, et al
    FOXO transcription factors both suppress and support breast cancer progression.
    Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2511.
    PubMed     Text format     Abstract available
    
    
    
54. HAO J, Yan F, Zhang Y, Triplett A, et al
    Expression of adipocyte/macrophage fatty acid binding protein in tumor associated macrophages promotes breast cancer progression.
    Cancer Res. 2018 Feb 6. pii: 0008-5472.CAN-17-2465.
    PubMed     Text format     Abstract available
    
    
    January 2018
55. WERFEL TA, Wang S, Jackson MA, Kavanaugh TE, et al
    Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-2388.
    PubMed     Text format     Abstract available
    
    
    
56. JIAO X, Velasco-Velazquez MA, Wang M, Li Z, et al
    CCR5 governs DNA damage and breast cancer stem cell expansion.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0915.
    PubMed     Text format     Abstract available
    
    
    
57. LUDWIK KA, McDonald OG, Brenin DR, Lannigan DA, et al
    ERalpha-mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-2063.
    PubMed     Text format     Abstract available
    
    
    
58. ZHANG Y, Manjunath M, Zhang S, Chasman D, et al
    Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-3486.
    PubMed     Text format     Abstract available
    
    
    
59. NAGAHASHI M, Yamada A, Katsuta E, Aoyagi T, et al
    Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1423.
    PubMed     Text format     Abstract available
    
    
    
60. EVANS MK, Brown MC, Geradts J, Bao X, et al
    XIAP regulation by MNK links MAPK and NFkappaB signaling to determine an aggressive breast cancer phenotype.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1667.
    PubMed     Text format     Abstract available
    
    
    
61. SAHA M, Kumar S, Bukhari S, Balaji SA, et al
    AMPK-AKT double negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2090.
    PubMed     Text format     Abstract available
    
    
    
62. SARVI S, Patel H, Li J, Dodd GL, et al
    Kindlin-1 promotes pulmonary breast cancer metastasis.
    Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-1518.
    PubMed     Text format     Abstract available
    
    
    
63. NOUGAREDE A, Popgeorgiev N, Kassem L, Omarjee S, et al
    Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.
    Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-0846.
    PubMed     Text format     Abstract available
    
    
    December 2017
64. MAEDA T, Hiraki M, Jin C, Rajabi H, et al
    MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    Cancer Res. 2017 Dec 20. pii: 0008-5472.CAN-17-1636.
    PubMed     Text format     Abstract available
    
    
    
65. EKAMBARAM P, Lee JL, Hubel NE, Hu D, et al
    The CARMA3-Bcl10-MALT1 Signalosome Drives NF-kappaB Activation and Promotes Aggressiveness in Angiotensin II Receptor-positive Breast Cancer.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-1089.
    PubMed     Text format     Abstract available
    
    
    
66. SHARMA C, Wang HX, Li Q, Knoblich K, et al
    Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence.
    Cancer Res. 2017;77:6880-6890.
    PubMed     Text format     Abstract available
    
    
    
67. PAOLETTI C, Cani AK, Larios JM, Hovelson DH, et al
    Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.
    Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-2686.
    PubMed     Text format     Abstract available
    
    
    
68. TELONIS AG, Rigoutsos I
    Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1947.
    PubMed     Text format     Abstract available
    
    
    
69. EL-SHENNAWY L, Dubrovskyi O, Kastrati I, Danes JM, et al
    Coactivation of estrogen receptor and IKK-beta induces a dormant metastatic phenotype in ER-positive breast cancer.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1686.
    PubMed     Text format     Abstract available
    
    
    
70. WU Y, Zhang Z, Cenciarini ME, Proietti CJ, et al
    Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-1327.
    PubMed     Text format     Abstract available
    
    
    November 2017
71. HOU P, Li L, Chen F, Chen Y, et al
    PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
    PubMed     Text format     Abstract available
    
    
    
72. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Text format     Abstract available
    
    
    
73. BYRD TT, Fousek K, Pignata A, Szot C, et al
    TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
    Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
    PubMed     Text format     Abstract available
    
    
    
74. PAJIC M, Froio D, Daly S, Doculara L, et al
    miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-16-3105.
    PubMed     Text format     Abstract available
    
    
    
75. CAMPBELL TM, Castro MA, deOliveira KG, Ponder BA, et al
    ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 signalling to modulate estrogen responsiveness in breast cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1153.
    PubMed     Text format     Abstract available
    
    
    
76. CAREY JP, Karakas C, Bui T, Chen X, et al
    Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1494.
    PubMed     Text format     Abstract available
    
    
    
77. PALMER JR, Castro-Webb N, Bertrand K, Bethea TN, et al
    Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.
    Cancer Res. 2017;77:6462-6469.
    PubMed     Text format     Abstract available
    
    
    October 2017
78. PATIN EC, Soulard D, Fleury S, Hassane M, et al
    Type I IFN receptor signalling controls IL-7-dependent accumulation and activity of protumoral IL-17A-producing gammadeltaT cells in breast cancer.
    Cancer Res. 2017 Oct 25. pii: canres.1416.2017.
    PubMed     Text format     Abstract available
    
    
    
79. TURCOTTE M, Allard D, Mittal D, Bareche Y, et al
    CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
    Cancer Res. 2017;77:5652-5663.
    PubMed     Text format     Abstract available
    
    
    September 2017
80. ISHIHARA S, Inman DR, Li WJ, Ponik SM, et al
    Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells.
    Cancer Res. 2017 Sep 28. pii: canres.0569.2017.
    PubMed     Text format     Abstract available
    
    
    
81. YANG A, Qin S, Schulte BA, Ethier SP, et al
    MYC Inhibition depletes cancer stem-like cells in triple-negative breast cancer.
    Cancer Res. 2017 Sep 26. pii: canres.3452.2016.
    PubMed     Text format     Abstract available
    
    
    
82. TEO ZL, Versaci S, Dushyanthen S, Caramia F, et al
    Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple negative breast cancer.
    Cancer Res. 2017 Sep 25. pii: canres.2210.2017.
    PubMed     Text format     Abstract available
    
    
    
83. CHEN L, Chubak J, Boudreau DM, Barlow WE, et al
    Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: A SEER-Medicare analysis.
    Cancer Res. 2017 Sep 21. pii: canres.0687.2017.
    PubMed     Text format     Abstract available
    
    
    
84. DAVIES H, Morganella S, Purdie CA, Jang SJ, et al
    Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.
    Cancer Res. 2017;77:4755-4762.
    PubMed     Text format     Abstract available
    
    
    
85. KATZENELLENBOGEN BS, Zhao Y, Laws MJ, Sanabria Guillen V, et al
    Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors.
    Cancer Res. 2017 Sep 13. pii: canres.1265.2017.
    PubMed     Text format     Abstract available
    
    
    
86. DETHLEFSEN C, Hansen LS, Lillelund C, Andersen C, et al
    Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development.
    Cancer Res. 2017 Sep 8. doi: 10.1158/0008-5472.CAN-16-3125.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: